Astrocyte

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, April 2, 2024
8-K, Research, Cash, Prevalence, HNSCC, Patient, Biomarker, Microglia, Sale, Nature, Form 10-K, Cancer, Neuroinflammation, Neuron, Neoplasm, Cognition, Drug development, Head and neck cancer, Astrocyte, PFS, Security, Neurodegenerative disease, Pharmaceutical industry

ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.

Key Points: 
  • ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.
  • Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • Financial Results for the Year Ended December 31, 2023:
    Cash and Cash Equivalents and Marketable Securities.
  • The Company effected a 1-for-15 reverse stock split in Q3 2023 and 1-for-14 reverse stock split in Q1 2024.

Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Blood pressure, EEG, Epilepsy, Bradycardia, Trevena, Rat, Neuropathic pain, Seizure, Central nervous system, Patient, CNS, TMS, Hospital, Sale, Chronic pain, NIH, IND, POC, Safety, Astrocyte, Status epilepticus, Neuroinflammation, Pharmaceutical industry

CHESTERBROOK, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2023 and provided an overview of its recent operational highlights.

Key Points: 
  • Given performance to date, we are reducing commercial support and reviewing alternatives for OLINVYK to preserve capital,” said Carrie Bourdow, President and CEO of Trevena.
  • OLINVYK will remain available for purchase by customers, who can continue to order the product through their normal channels.
  • In a review of safety and tolerability across both studies, TRV045 was well tolerated with results generally consistent with prior first-in-human studies.
  • For the fourth quarter of 2023, the Company reported a net loss attributable to common stockholders of $16.5 million, or $1.06 per share, compared to $7.0 million, or $0.73 per share in the fourth quarter of 2022.

Induced Pluripotent Stem Cells Market Report, Featuring Historical Revenue Data for 2021 and 2022, Estimated Figures for 2023, and Compound Annual Growth Rates (CAGRs) through 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Cell, Stem cell, Fibroblast, B cell, Enzyme, Serum, Drug discovery, Row, Good manufacturing practice, Differentiable function, Neuron, GMP, Hepatocyte, Regenerative medicine, Medium (website), Antibody, Drug development, Geography, Astrocyte, IPSC, Endothelium

For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.

Key Points: 
  • For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.
  • An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.
  • The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW).
  • The report will provide details with respect to induced pluripotent stem cells.

Boston Harbor Angels Celebrates 20 Years of Angel Investing, Setting New Benchmarks in Innovation and Entrepreneurship

Retrieved on: 
Tuesday, March 19, 2024
Elizabeth Banks, Growth, Family, Astrocyte, Entrepreneurship, BHA

BOSTON, March 19, 2024 /PRNewswire/ -- Boston Harbor Angels (BHA) proudly commemorates two decades of catalyzing innovation and fostering entrepreneurial growth within the Boston ecosystem.

Key Points: 
  • BOSTON, March 19, 2024 /PRNewswire/ -- Boston Harbor Angels (BHA) proudly commemorates two decades of catalyzing innovation and fostering entrepreneurial growth within the Boston ecosystem.
  • Over the past 20 years, the organization has cultivated a dynamic network of investors, industry experts, and most importantly their entrepreneurs.
  • "As we celebrate our 20th anniversary," remarks President and CEO of BHA, Ziad Moukheiber , "we reflect on our and our founders hard work in angel investing.
  • Boston Harbor Angels reaffirms its commitment to investing for a better world as it commemorates 20 years.

Cerevance Announces Presentation at AD/PD™ 2024 International Conference

Retrieved on: 
Tuesday, February 27, 2024
Shift, Therapy, Epigenomics, Central nervous system, Alzheimer's disease, KCNK10, Astrocyte, Date, Conference, Mechanism, CNS, Gene, DSM-IV codes

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.
  • Overview: The NETSseq platform produces deep transcriptomic and epigenomic profiles from post-mortem human brain tissue.
  • One of these genes, KCNK10, is specifically expressed in astrocytes and oligodendrocytes, and its role in regulating glutamate uptake has been validated.
  • Therapeutic Targets, Mechanisms for Treatment: Astroglia; Poster Shift 2: Friday, March 8 - Saturday, March 9, 2024

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis

Retrieved on: 
Wednesday, January 17, 2024
Woman, Neoplasm, Patient, Inflammasome, ASC, Therapy, Astrocyte, Breast cancer, NLRP3, Metastasis, Quality of life, Triple-negative breast cancer, Inflammation, Personality, TNBC, Brain, Cancer, Medical imaging

Published data demonstrate that inflammasome activation increases proliferation of TNBC cells in the brain, which was prevented by inhibition of NLRP3 inflammasomes in both mouse and human models.

Key Points: 
  • Published data demonstrate that inflammasome activation increases proliferation of TNBC cells in the brain, which was prevented by inhibition of NLRP3 inflammasomes in both mouse and human models.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammation.
  • WESTON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed journal, Acta Neuropathologica Communications, demonstrating that inflammasome activation enhances cancer metastasis to the brain in women with TNBC.
  • In the paper titled, “Inflammasome activation in peritumoral astrocytes is a key player in breast cancer brain metastasis development,” the authors evaluated in vivo and in vitro brain metastasis models, as well as human cultures of astrocytes and TNBC cells.

Apertura Gene Therapy Unveils Novel Engineered AAV Capsids Targeting Human Transferrin Receptor 1 for Neurological Gene Therapy Delivery

Retrieved on: 
Thursday, January 4, 2024
Health, Neurology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Liver, Traffic barrier, Broad Institute, Transferrin receptor 1, DSM-IV codes, BBB, Vector, MIT, Astrocyte, Brain, Transferrin, Endothelium, Gene expression, AAV, Engineering, CNS, Harvard University, Transport, Central nervous system, Iron, Patient, Psychiatry, Gene therapy, Neuron, Vaccine

Apertura Gene Therapy , a biotechnology company opening opportunities in genetic medicine for treating debilitating diseases with limited options, today unveiled its proprietary engineered Adeno-Associated Virus (AAV) capsids that bind to the human Transferrin Receptor 1 (TfR1).

Key Points: 
  • Apertura Gene Therapy , a biotechnology company opening opportunities in genetic medicine for treating debilitating diseases with limited options, today unveiled its proprietary engineered Adeno-Associated Virus (AAV) capsids that bind to the human Transferrin Receptor 1 (TfR1).
  • This transportation mechanism mediates crossing of the blood-brain barrier (BBB) to enable gene therapy delivery throughout the central nervous system (CNS).
  • “Our TfR1 capsids, with their well-characterized mechanism of action, offer the unique advantage of significantly reducing human translation risk – a major historical challenge of engineering novel AAV capsids.
  • Apertura is currently advancing two programs utilizing its TfR1 capsids for undisclosed neurologic conditions and is leveraging its platform technologies to engineer novel payloads to regulate genetic expression and develop additional AAV capsids targeting specific human receptors.

Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Retrieved on: 
Wednesday, December 6, 2023
Motor cortex, Food, ALS, Survival, Cerebrospinal fluid, IND, Plasma, Small RNA, Astrocyte, Spinal cord, Therapy, Animal, SOD1, Biomarker, Neurology, Neuron, Pharmaceutical industry

LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program.

Key Points: 
  • LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program.
  • The Company anticipates filing an investigational new drug (IND) application with the Food and Drug Administration for the candidate in mid-2025.
  • Voyager’s SOD1-ALS lead candidate combines a highly potent siRNA construct to decrease the expression of SOD1 with an IV-delivered, blood-brain barrier-penetrant TRACER™ capsid.
  • The candidate demonstrated robust knockdown of SOD1 across all levels of the spinal cord and motor cortex.

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Encephalitis, Nature, HD, Eurosport 1, Patient, Research, Neuron, Dementia, Conference, Cash, ORR, Cognition, Drug discovery, Cancer, Doctor of Philosophy, Form 10-Q, Glial fibrillary acidic protein, FCMI, Prevalence, Astrocyte, GFAP, Microglia, Blood, Head and neck cancer, Three Months, Completeness, Risk, PFS, Merck, L.L.C, SEMA4D, Clinical trial, Security, Drug, Drug development, Patent, SIGNAL, Biomarker, Brain, CCR8, Plasma, Disease, Private placement, Neurodegenerative disease, Private, Neoplasm, G protein-coupled receptor, Cryptocurrency, Pharmaceutical industry, Medical imaging, Vaccine, HNSCC

ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update on progress in key programs.

Key Points: 
  • ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update on progress in key programs.
  • The potential impact of the AD program on Vaccinex valuation and financial resources make this Vaccinex’s most important near-term catalyst.
  • On August 22, 2023, Vaccinex completed a Private Placement and issued approximately 0.20 million shares1 of common stock for aggregate proceeds of $0.7 million.
  • Similarly, on September 22, 2023, Vaccinex completed a Private Placement and issued approximately 0.25 million shares of common stock for aggregate proceeds of $0.6 million.

Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
Potassium, Gene expression, Therapy, Pathology, KCNJ10, CNS, Society, Disease, Date, Cerev Del, Annual general meeting, Astrocyte, Central nervous system, Vaccine, Neuroscience

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster presentation at the Neuroscience 2023 Annual Meeting presented by the Society for Neuroscience, taking place in Washington, D.C., November 11 – 15th, 2023.

Key Points: 
  • BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster presentation at the Neuroscience 2023 Annual Meeting presented by the Society for Neuroscience, taking place in Washington, D.C., November 11 – 15th, 2023.
  • Overview: Gene expression relevant to human disease pathology can be observed using Cerevance’s proprietary NETSseq platform.
  • Data from this approach demonstrated that KCNJ10 is expressed in astrocytes from post-mortem brain tissue of Alzheimer’s and Parkinson’s disease donors and is increased in disease.
  • Session and Date and Time: Potassium Channels; November 15th, 8am – 12pm ET